US 12,460,032 B2
Compositions with high refractive index and Abbe number
Azaam Alli, Jacksonville, FL (US); Bart Johnson, Laguna Beach, CA (US); Scott L. Joslin, Ponte Vedra Beach, FL (US); and Ghulam Maharvi, Jacksonville, FL (US)
Assigned to Johnson & Johnson Surgical Vision, Inc., Irvine, CA (US)
Filed by Johnson & Johnson Surgical Vision, Inc., Irvine, CA (US)
Filed on Mar. 12, 2024, as Appl. No. 18/603,133.
Application 18/603,133 is a continuation of application No. 18/190,018, filed on Mar. 24, 2023, granted, now 11,958,923.
Application 18/190,018 is a continuation of application No. 16/865,055, filed on May 1, 2020, granted, now 11,667,742, issued on Jun. 6, 2023.
Claims priority of provisional application 62/843,054, filed on May 3, 2019.
Prior Publication US 2024/0218102 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C08F 220/40 (2006.01); G02B 1/04 (2006.01)
CPC C08F 220/40 (2013.01) [G02B 1/041 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An ophthalmic device comprising a composition made by free radical polymerization of a reactive monomer mixture, the reactive monomer mixture comprising:
(a) at least one cycloaliphatic (meth)acrylate;
(b) at least one aliphatic (meth)acrylate comprising a linear or branched unsubstituted alkyl group; and
(c) tricyclo[5.2.1.02,6]decanedimethanol di(meth)acrylate as a cycloaliphatic cross-linking agent;
wherein the composition exhibits a refractive index of at least 1.45 and an Abbe number of at least 39; and
wherein the ophthalmic device comprises an intraocular lens, contact lens, corneal inlay, corneal outlay, or corneal insert.